Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd

₹ 288 -0.43%
21 May 9:33 a.m.
About

Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]

Key Points

Market Position
The Co. is the 1st Indian enzyme company with 2nd highest market share in India. It is the 2nd listed integrated enzyme player globally. [1]

  • Market Cap 3,217 Cr.
  • Current Price 288
  • High / Low 571 / 258
  • Stock P/E 24.5
  • Book Value 127
  • Dividend Yield 1.38 %
  • ROCE 13.0 %
  • ROE 9.55 %
  • Face Value 2.00

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 32.6%

Cons

  • The company has delivered a poor sales growth of 7.48% over past five years.
  • Company has a low return on equity of 10.0% over last 3 years.
  • Promoter holding has decreased over last 3 years: -9.62%
  • Working capital days have increased from 207 days to 398 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
132 121 139 142 139 147 158 161 158 155 146 169 167
91 90 99 100 95 103 107 107 102 103 104 114 122
Operating Profit 40 31 40 42 44 44 51 54 55 51 42 55 46
OPM % 31% 26% 29% 29% 32% 30% 32% 33% 35% 33% 29% 33% 27%
3 2 4 9 7 7 6 14 -6 7 10 8 9
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1
Depreciation 9 9 9 9 8 9 9 9 9 9 9 9 10
Profit before tax 34 24 34 40 42 41 48 59 40 49 42 53 43
Tax % 26% 26% 23% 31% 24% 29% 27% 28% 25% 28% 21% 27% 38%
25 18 26 28 32 29 35 42 30 35 33 39 27
EPS in Rs 2.19 1.60 2.34 2.63 2.87 2.58 3.08 3.74 2.53 3.05 2.94 3.37 2.37
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
239 222 293 329 391 420 444 502 529 541 624 637
189 131 155 177 226 236 241 269 327 382 418 442
Operating Profit 50 91 138 152 165 184 203 233 203 158 206 194
OPM % 21% 41% 47% 46% 42% 44% 46% 46% 38% 29% 33% 31%
1 1 -3 3 1 5 6 9 6 21 21 33
Interest 13 9 8 4 9 5 4 3 3 3 4 4
Depreciation 10 9 9 13 18 21 26 29 35 35 35 37
Profit before tax 28 74 118 137 139 162 179 210 171 140 188 187
Tax % 23% 31% 35% 32% 33% 28% 26% 28% 28% 26% 27% 28%
21 51 77 93 94 116 133 151 124 104 137 134
EPS in Rs 1.85 4.60 6.97 8.20 8.07 9.95 11.58 13.06 10.70 9.45 11.92 11.72
Dividend Payout % 6% 4% 3% 5% 6% 6% 5% 7% 9% 11% 43% 44%
Compounded Sales Growth
10 Years: 11%
5 Years: 7%
3 Years: 6%
TTM: 2%
Compounded Profit Growth
10 Years: 10%
5 Years: 0%
3 Years: 3%
TTM: -9%
Stock Price CAGR
10 Years: %
5 Years: 14%
3 Years: 1%
1 Year: -22%
Return on Equity
10 Years: 14%
5 Years: 11%
3 Years: 10%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 22 22 22 22 22 22 22 22 22 22 22 22
Reserves 145 188 256 442 537 657 817 949 1,066 1,213 1,302 1,398
167 115 101 54 67 35 28 28 35 34 47 39
73 92 71 65 102 91 104 150 137 142 150 161
Total Liabilities 406 417 450 583 727 805 971 1,149 1,260 1,411 1,521 1,621
287 287 285 421 491 495 563 604 619 649 650 679
CWIP 2 5 7 8 11 10 10 10 15 22 41 22
Investments 0 0 0 0 0 111 124 121 102 360 403 480
117 125 158 153 226 188 275 414 524 380 427 441
Total Assets 406 417 450 583 727 805 971 1,149 1,260 1,411 1,521 1,621

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
43 54 93 107 116 129 141 163 122 140 141 142
-25 -15 -10 -60 -60 -124 -43 -27 2 -286 -65 -89
-20 -36 -63 -65 -2 -43 -39 -26 -48 -26 -59 -73
Net Cash Flow -1 2 21 -18 54 -38 60 109 75 -171 17 -19

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 49 61 52 55 55 51 61 63 61 68 58 66
Inventory Days 387 403 358 352 339 363 361 346 402 343 375 378
Days Payable 81 89 68 57 78 46 43 56 60 67 40 41
Cash Conversion Cycle 356 374 342 351 315 369 379 353 404 344 393 403
Working Capital Days 5 -4 40 106 82 90 100 104 122 117 106 398
ROCE % 12% 25% 36% 31% 25% 24% 22% 22% 15% 12% 15% 13%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
52.70% 49.88% 49.88% 49.88% 46.52% 45.92% 43.62% 43.50% 43.02% 42.95% 42.92% 43.08%
18.72% 21.68% 21.74% 21.86% 21.89% 22.27% 22.54% 23.01% 12.03% 12.63% 12.57% 11.90%
6.26% 5.60% 5.64% 5.73% 7.58% 6.49% 6.98% 7.56% 8.08% 8.02% 8.17% 8.19%
22.32% 22.86% 22.76% 22.54% 24.02% 25.34% 26.88% 25.95% 36.87% 36.40% 36.31% 36.82%
No. of Shareholders 84,37684,27781,18377,53775,05272,64273,03468,64065,22266,75867,35165,322

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls